Chunbo Co., Ltd. Overview
Chunbo is a Korean fine-chemical synthesis and purification company. It has moved from niche display and semiconductor process chemicals to specialty lithium salts and electrolyte additives for lithium-ion batteries. Its main technical claim is that it was the first company worldwide to commercialize LiFSI (the "F-electrolyte"). Sources date this to 2016 or 2017. It also makes LiPO2F2 (the "P-electrolyte"), on which Korean battery-cell export volumes have tracked its revenue closely, together with LiDFOP, LiBOB and a broad range of film-forming additives (VC, FEC, PS, ESA and others). A smaller electronic-materials franchise (LCD etchant additives, OLED common-layer materials, semiconductor process chemicals, oxalic acid) supplies most of the operating profit at around 20% margins. Since 2021 the company has spent heavily on a greenfield LiFSI and additive complex in Saemangeum through subsidiary Chunbo BLS, financed largely with mezzanine capital. The 2023–2025 downturn in electrolyte prices, combined with plant delays, eliminated profits. The 2026 investment case depends on ramping LiFSI supply to a North American OEM's 4680 cell program and on a recovery in Chinese electrolyte demand.
What the company does
Chunbo is a specialty-chemical manufacturer working in three technology domains that its IR material calls IT, BT and GT. In its own descriptions it supplies:
-
additives used in manufacturing LCD and OLED display panels;
-
raw materials for EMC (epoxy molding compound) resins;
-
semiconductor process materials;
-
oxalic acid;
-
pharmaceutical raw materials and intermediates;
-
secondary-battery materials (lithium salts and electrolyte additives);
-
other specialty chemicals, including tire additives and materials for chemically strengthened display glass.
Source: company description as summarized by StockHub and Kiwoom (2026); Chunbo IR decks 2022–2024.
The company describes itself as a "comprehensive precision chemical materials company." In a 2023 investor meeting, its CFO said the company's real identity is fine chemicals: it is strong in synthesis and purification, it often holds first-mover or near-monopoly positions in the molecules it makes, and its products have historically carried market shares near 90% with operating margins near 20% (Digital Daily, 30 Apr 2023). Third-party profiles also call Chunbo Korea's only oxalic-acid producer, supplying Korean chipmakers and exporting to Japan and Taiwan, and the world's largest producer of 5-aminotetrazole (ATZ) (Innoforest company profile).
Business model and revenue model
The revenue model is product-based and B2B: it sells high-purity chemicals by weight under supply agreements. There is no material service, subscription or licensing revenue disclosed. Key features:
Battery materials (~51–58% of revenue): Lithium salts and additives are sold to electrolyte makers and battery-cell makers. Pricing is linked partly to lithium carbonate and LiPF6 market prices, which caused the 2023–2024 collapse in average selling prices. Broker research in late 2025 and 2026 points to price pass-through clauses: Mirae Asset expected roughly 20% pass-through of raw-material increases into selling prices from H2 2026 (Mirae Asset via HelloT, 13 Apr 2026).
Electronic materials (~29–38%): Etchant additives, OLED intermediates and semiconductor chemicals are qualified into specific customer processes. This creates high switching costs and stable margins; Mirae Asset cites operating margins around 20% (Apr 2026).
Pharma intermediates, fine chemicals and other (~8–13%): Custom synthesis and catalog chemicals, including ATZ and oxalic acid.
Value-chain position
In the battery chain, Chunbo sits upstream of electrolyte formulators (e.g., Dongwha Electrolyte, Enchem, Soulbrain, and Chinese formulators) and battery-cell makers. It supplies the functional salts and additives, typically a few percent of electrolyte weight, that set cycle life, high-voltage stability, low-temperature performance and safety. LiFSI can also be used as a co-salt alongside, or partial replacement for, LiPF6. In display and semiconductor chains it is a tier-2 or tier-3 chemical supplier to panel makers, chemical formulators and fabs.
Customer types and end-markets
| End-market | Customer types | Named customers (as disclosed or reported) | Source |
|---|---|---|---|
| EV and ESS batteries | Cell makers; electrolyte formulators | LG Energy Solution, Samsung SDI, SK On, CATL, BYD, Panasonic, Tesla | CFO remarks, Digital Daily (30 Apr 2023) |
| EV batteries (2020-era) | Cell makers | LGES, Samsung SDI, SK Innovation, CATL; the batteries went into BMW i3/i8, Chevrolet Volt, VW e-Golf | TheElec (25 Jan 2021) |
| China (2025–26) | Cell makers | EVE Energy (LiPO2F2 volume growth in Q4 2025) | Kiwoom (2 Jan 2026) |
| North American OEM | OEM in-house cell production | F-electrolyte shipments since early 2026, believed by Mirae Asset to go to Tesla's 4680 cells for the Cybercab | Mirae Asset via HelloT (13 Apr 2026); Kiwoom (27 Aug 2026) |
| Display | Panel makers and etchant formulators | Not named in sources | — |
| Semiconductors | Korean chipmakers (oxalic acid, process chemicals) | Not named | Innoforest |
| Pharma | Pharmaceutical companies | Not named | StockHub/company description |
Independent characterization
Chunbo is a capable small-molecule chemist that made a large, debt-financed bet on a single application. Battery materials grew from about KRW 2bn of revenue in 2015 (Hana Financial Investment, cited by Asia Economy, Oct 2018) to around 68% of group revenue by 2022 (Dealsite, 25 Apr 2023). That transformed Chunbo from a steady mid-teens-margin specialty house into a cyclical, capital-intensive battery-materials company. Three things then went wrong at once: the 2023–2024 lithium price collapse, Chinese overcapacity in LiFSI and additives, and delays at the Saemangeum plant. Together they turned an operating margin of 17–19% (FY2021–FY2022) into losses (FY2023–FY2024). Since 2025 the business has returned to marginal operating breakeven. Net losses continue, driven by non-cash derivative losses on convertible bonds and by interest. The electronic-materials franchise is the stable core that partly subsidizes the battery ramp.
Strategy
Stated strategic themes (paraphrased from IR materials and management remarks)
-
Leadership in next-generation lithium salts. Scale LiFSI as the successor or co-salt to LiPF6 and hold leading positions in LiPO2F2, LiDFOP and LiBOB (Chunbo IR decks 2022–2024).
-
Cost innovation to beat Chinese competitors. Management claimed a new LiFSI process cutting manufacturing cost by more than 50% (Digital Daily, Apr 2023). Research Alum (Aug 2025) cites a lithium-carbonate-based process with savings of at least 30%. Hi Investment (Nov 2023) cites 30–50%. The process is also said to recycle all by-products.
-
Profitability target. A 25% operating margin target for new lithium-salt products, through cost innovation and process optimization (Quartr Q2 2024 and Q3 2025 summaries; Kiwoom, Jul 2024).
-
Geographic diversification. Grow the US and Europe to 60% of revenue (target stated Aug 2023). This has not been achieved.
-
Supplying non-Chinese supply chains. Position as a non-Chinese source of lithium salts and additives for North American supply chains. The Feb 2026 three-way cooperation with Dongwha Electrolyte and PGT is the formal expression (Digital Daily, 10 Feb 2026).
-
Diversified fine-chemical base. Keep electronic materials, pharma and fine chemicals as stable profit pools (Naver/AI report, May 2026).
Initiatives in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| 6th-series CB and KRW 100bn hybrid capital | Q4 2024 | Refinanced the 2022 CB/BW put; strengthened equity through the hybrid | Valueline/DataHero; Quartr |
| Chunbo BLS external capital (1) | Jul 2025 | Reported KRW 150bn CB subscription by a Mirae Asset Venture Investment fund (SKS-Mirae Asset corporate restructuring PEF) | IB Tomato (24 Jul 2025) |
| Chunbo BLS external capital (2) | Jun 2026 | KRW 78.2bn CB from Mirae Asset Renaissance New Energy PE; KRW 54.7bn earmarked for facilities | IB Tomato (9 Jun 2026) |
| North American LiFSI supply | From early 2026 | F-electrolyte for a North American OEM's in-house 4680 cells (Cybercab), per Mirae Asset | HelloT (13 Apr 2026) |
| North American supply-chain alliance | 10 Feb 2026 | With Dongwha Electrolyte and PGT, linking LiPF6 (PGT), salt-based additives (Chunbo) and finished electrolyte (Dongwha, Tennessee) | Digital Daily (10 Feb 2026) |
| Price pass-through | 2025–2026 | Customer negotiations to pass through LiPF6 and lithium increases from Q1 2026; about 20% pass-through expected from H2 2026 | Kiwoom (Jan 2026); Mirae Asset (Apr 2026) |
| Saemangeum ramp | 2,026 | LiFSI and FEC lines contributing revenue; losses continue on fixed costs | Kiwoom (Aug 2026) |
ESG commitments. No formal emissions targets or sustainability-linked financing were identified.
Cost programs. No quantified group cost-reduction program was found beyond the process-cost claims above.
Medium-term targets and guidance
No formal numerical revenue or profit guidance for 2026–2027 was found in the sources reviewed. Historical aspirational targets:
-
KRW 400bn+ revenue for 2023 (CFO, Apr 2023). Actual: KRW 182.7bn.
-
Saemangeum to make Chunbo BLS "a KRW 1 trillion annual-revenue company" (Lee Sang-yul, Jul 2021).
-
LiFSI revenue plan of KRW 58bn → 154bn → 800bn → 2.4tn over ten years (2Q21 IR).
These targets have proved far too optimistic. They should be treated as aspirations, not guidance.
Products & Services
The company does not publish prices. Launch years are given where IR material states them.
Secondary-battery materials
| Product | Abbrev. / internal name | Function / capability | Target customer | Status / year | Source |
|---|---|---|---|---|---|
| Lithium bis(fluorosulfonyl)imide | LiFSI ("F-electrolyte") | Specialty lithium salt with higher conductivity and thermal and hydrolytic stability than LiPF6 and better low-temperature performance. Used with high-nickel cathodes, silicon anodes, high-spec ESS and long-warranty IT cells. Used as co-salt or additive. | Cell makers, electrolyte formulators; North American OEM (2026) | Commercialized 2016/2017 (first worldwide); Saemangeum lines ramping 2026 | Research Alum via Asia Economy (25 Aug 2025); Chunbo IR 2024 |
| Lithium difluorophosphate | LiPO2F2 ("P-electrolyte") | Film-forming salt additive improving cycle life and high-voltage performance in NCM cells. Chunbo's flagship product; Korean LiPO2F2 export data are used as a proxy for its revenue. | Cell makers (Korean and Chinese, incl. CATL, EVE Energy) | Mass production; new-process plant planned (2024 IR); +30% QoQ volume in Q2 2026 (est.) | iM Securities (2025); Kiwoom (Aug 2026) |
| Lithium difluoro(oxalato)phosphate | LiDFOP ("D-electrolyte") | Salt additive for interphase stability | Cell makers | Commercial | Hi Investment (Jan 2024) |
| Lithium bis(oxalato)borate | LiBOB ("B-electrolyte") | Salt additive for high-temperature and cathode protection | Cell makers | Commercial | Hi Investment (Jan 2024); Chunbo 4Q21 IR deck |
| Vinylene carbonate | VC | SEI-forming anode additive | Electrolyte makers | 6,000 t VC/FEC mass production planned for Q3 2023 | Yuanta (Apr 2023) |
| Fluoroethylene carbonate | FEC | SEI additive, important for silicon anodes | Electrolyte makers | Saemangeum FEC volumes contributing in 2026 | Kiwoom (Aug 2026) |
| 1,3-Propane sultone | PS | Sulfur-based SEI and CEI additive | Electrolyte makers | 4,000 t planned at Gunsan (Saemangeum) | Chunbo 2Q23 IR deck |
| Ethylene sulfate (inferred) | ESA | Sulfate film-forming additive | Electrolyte makers | Listed in IR item list | Chunbo 1Q23 IR (BofA conference) |
| Tris(trimethylsilyl) borate | TMSB | Cathode-protective additive | Electrolyte makers | Commercial (2021) | TheElec (Jan 2021) |
| Nitrile additives | AN, SN, DPN | Additives suppressing swelling and overcharge | Electrolyte makers | Commercial (2021) | TheElec (Jan 2021) |
| LiFSI electrolyte Al-corrosion inhibitor | — | Additive that offsets LiFSI's aluminium-collector corrosion | Electrolyte formulators | Development / portfolio | Chunbo 2Q24 IR deck |
| CNT slurry (anode additive) | — | Conductive additive | Cell makers | IR (Aug 2022) targeted 1Q 2025 | Chunbo 2Q22 IR deck |
| Solid-electrolyte materials | LLZO oxide; polymer electrolytes | Next-generation research | — | R&D | Chunbo 2Q24 IR deck |
| Item | Detail | Source |
|---|---|---|
| Total electrolyte capacity, 2020 | 1,840 t | TheElec (Jan 2021) |
| Total capacity 2022 → 2023 plan | 4,700 t → 17,000 t | Yuanta (Apr 2023) |
| LiFSI plan (Aug 2022 IR) | 1,000 → 5,000 → 5,000 → 10,000 → 21,000 (staged 2022–2026) | Chunbo 2Q22 IR deck |
| LiFSI plan (Aug 2023 IR) | 10,000 → 20,000 → 20,000 → 50,000 (Gunsan Saemangeum) | Chunbo 2Q23 IR deck |
| LiPO2F2 plan | 3,000 → 5,000 by 2026 | Chunbo 2Q23 and 4Q21 IR decks |
| CFO target (Apr 2023) | LiFSI capacity 10,000 t → 50,000 t through 2025 and 2027 expansions; 60% LiFSI market share target | Digital Daily (30 Apr 2023) |
The company claims "the largest number of electrolyte additive items globally" (Komachine).
Capacity disclosures (plans, tonnes per year). These are historical plans, and several were delayed.
Kiwoom (Aug 2026) describes Saemangeum utilization as low, with fixed-cost absorption still negative.
Electronic materials
| Product | Function | Customers | Notes | Source |
|---|---|---|---|---|
| LCD etchant additives | Additives for high-definition LCD etching | Panel makers, etchant formulators | Original core business (2008) | Chunbo IR 2020–2022 |
| OLED common-layer materials (e.g., H-369, H-668) | Hole and common-layer materials | OLED panel supply chain | Since 2013 | Chunbo 3Q22 and 1Q23 IR decks |
| OLED emitting-material intermediates | High-purity intermediates | OLED material makers | — | Naver/AI report (May 2026) |
| Semiconductor fine-pattern and cleaning materials | Process chemicals | Chip supply chain | Since 2011 | Chunbo 3Q22 IR deck |
| Oxalic acid | Semiconductor and industrial uses | Korean chipmakers; exports to Japan and Taiwan | Described as Korea's only producer | Innoforest |
| EMC resin raw materials | Semiconductor packaging | Packaging-material makers | — | Company description (StockHub) |
| Chemically strengthened glass materials | Display cover glass | Glass processors | — | Company description (StockHub) |
Fine chemicals and pharmaceutical materials
| Product | Function | Notes | Source |
|---|---|---|---|
| 5-Aminotetrazole (ATZ) | Specialty intermediate | Described as global #1 producer | Innoforest; Naver/AI report (May 2026) |
| Tire additives | Specialty chemicals | — | Company description |
| Pharmaceutical raw materials and intermediates | Custom synthesis | About 3% of revenue (Q2 2026) | Butler; company description |
Financial Narrative
Units are KRW bn unless stated. FY = calendar year. The sources are OpenDART-derived aggregators (Butler, Valueline/DataHero, Bullstory), Quartr earnings summaries and broker reports, as noted. Where sources conflict, both figures are shown.
Income statement — core series
Sources: Butler (OpenDART) for revenue, OP and NI for FY2021–FY2025. FY2021 growth is derived from FY2020 revenue of KRW 155.5bn (TheElec). Margins are derived. Bullstory (OpenDART) confirms FY2025 revenue of KRW 133,849,589,627, OP of KRW 3,710,962,944 and net loss of KRW 60,014,543,541.
Revenue CAGR FY2021–FY2025: –16.2% per year (derived). Revenue in FY2025 was 49% of FY2021 and 41% of the FY2022 peak.
Income statement — additional lines
Notes on this table:
- It is shown as 0 only as a placeholder for charting and should be treated as not disclosed in sources reviewed.
EPS FY2025: Valueline shows –5,550; Quartr's Q4 2025 summary shows –5,752. The difference likely reflects weighted-average share counts during CB conversions. Both are shown.
Sources: EPS FY2022: Hanwha (May 2024). EPS FY2023–FY2024 and owners' NI: Kiwoom (Jan 2026). Pre-tax FY2023–FY2024: Kiwoom. EBITDA FY2022–FY2023: Hanwha and Kiwoom. FY2024 EBITDA: Kiwoom. FY2025 EBITDA is derived as OP 3.7 + D&A 22.8 (Valueline cash-flow statement); Kiwoom's January 2026 estimate was 25.4.
Interpretation of FY2025. The KRW 63.7bn gap between operating profit (+3.7bn) and the net loss (–60.0bn) is mostly non-cash:
-
Net derivative losses of about KRW 46.6bn, consistent with fair-value remeasurement of CB conversion features as the share price rose about 35% in 2025 (Kiwoom: 1-year return +35.2% to 30 Dec 2025).
-
Interest expense of KRW 22.6bn, against cash interest paid of only KRW 4.9bn per the cash-flow statement. Most interest is accretion on mezzanine instruments.
The reported net loss therefore overstates cash economic losses. It does, however, signal continuing equity dilution, because conversions feed directly into share count.
Quarterly trajectory
Sources: Q1 2025 (Quartr; iM 30 May 2025); Q2 2025 derived from H1 2025 (revenue 68.6, OP 5.7; Quartr); Q3 2025 (iM, 21 Nov 2025); Q4 2025 derived as FY2025 minus 9M 2025 (9M revenue 99.3, 9M OP 6.3; Quartr); Q1 2026 (Quartr); Q2 2026 (Kiwoom via StockHub, 27 Aug 2026). Q4 2025 OP of –2.6bn is derived; Kiwoom had previewed +0.9bn.
H1 2026: revenue KRW 91.8bn (+34% YoY, derived); operating loss KRW 7.2bn; net loss about KRW 12.3bn; cash KRW 16.0bn (Quartr Q2 2026 summary). Quartr's headline describes H1 2026 revenue as "down 31%" and compares the net loss with KRW 32.3bn. Both appear to be errors: the 32.3bn is the FY2024 full-year loss, and H1 2025 revenue was KRW 68.6bn.
Balance sheet
Source: Valueline/DataHero (DART-based). Total debt, short/long split, net debt and working capital are derived.
Definitions and caveats:
Total debt: excludes lease liabilities and the KRW 100bn of hybrid securities, which are classified as equity. If the hybrid is counted as debt, FY2025 adjusted net debt is about KRW 321.8bn.
- Quartr reports a net debt-to-capital ratio of 43.0% (FY2025) and 44.7% (H1 2026).
Balance-sheet commentary:
Investment cycle: From FY2022 to FY2024, PP&E more than doubled (KRW 341.6bn → 705.1bn) as Saemangeum construction in progress peaked at KRW 549.3bn. In FY2025, KRW 376bn of construction in progress moved into service: building assets rose from KRW 41.3bn to 157.4bn and "other" PP&E from 46.6bn to 244.1bn. This drives the step-up in depreciation (COGS depreciation from KRW 18.9bn to 35.0bn on a TTM basis by Jun 2026).
Liquidity has thinned: Cash plus short-term instruments fell from KRW 266bn (FY2022) to KRW 49.5bn (FY2025), as short-term deposits funded the Q4 2024 CB/BW put redemptions and capex.
Refinancing risk is high: The current ratio is 0.39–0.45x and working capital is negative at KRW –194bn to –211bn. About 84% of financial debt is classified as current at H1 2026, partly because the 6th-series CB is classified as current (derived).
Equity has been rebuilt through conversions, not earnings: Share premium rose from KRW 86.4bn (FY2024) to KRW 238.3bn (H1 2026). Retained earnings fell from KRW 218.6bn (FY2022) to KRW 75.3bn (H1 2026).
Goodwill is zero: and intangibles are negligible. The asset base is almost entirely tangible manufacturing assets.
Cash flow
Sources: Valueline/DataHero (DART-based); Bullstory confirms FY2025 OCF of KRW 8.03bn. Valueline shows its own FCF of KRW –9.4bn on a different definition.
Trailing 12 months to March 2026: OCF KRW 6.4bn, capex KRW 25.5bn (Valueline).
- Rolling data imply that heavy capex continued through 2024: trailing-12-month capex to March 2025 was KRW 97.7bn. The FY2021–FY2023 build-out was funded by the KRW 300bn 2022 CB/BW and bank borrowings.
Investing inflows in FY2025: reflect redemption of short-term deposits, not divestitures.
Financing outflows in FY2025: include KRW 80.6bn of bond repayment.
Ratio analysis
Calculation notes:
ROE: FY2022 and FY2023 match Hanwha (11.9%, –13.1%). FY2024 and FY2025 are derived from owners' NI over average owners' equity. Quartr reports –9.8% (FY2024) and –15.2% (FY2025); Valueline shows –14.29% TTM.
Asset turnover: Computed on the same asset basis as ROA.
Trend commentary. The five years divide into two phases:
-
FY2021–FY2022 (expansion). Revenue grew sharply, operating margins were 17–19%, and leverage was low because CB proceeds were still held as deposits.
-
FY2023–FY2025 (contraction and refinancing). Lithium-linked price deflation halved revenue in FY2023. Delays at Saemangeum held back volumes. The Q4 2024 put window forced refinancing into a lower-strike CB, KRW 100bn of hybrid capital, and short-term bank lines.
The inflection in FY2025 was operational: OP turned positive on cost control and product mix. It was not financial. In 2026, revenue is growing again (Q2 2026 +54% YoY) but margins are negative while new assets depreciate at low utilization. On EBITDA, the business generated about KRW 26–27bn in FY2025 and TTM June 2026. That is enough to cover cash interest but not capex plus debt amortization without outside capital.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Ownership / notes | Source |
|---|---|---|---|
Chunbo Co., Ltd. | Listed parent; electronic materials, fine chemicals, pharma intermediates, legacy battery materials (Chungju) | Lee Sang-yul and related parties 55.9% | Kiwoom (Jan 2026) |
Chunbo BLS Co., Ltd. (천보비엘에스) | Saemangeum (Gunsan) LiFSI, additive and lithium-salt complex | Subsidiary. On full conversion of external CBs, outside holders could reach up to ~26% (per IB Tomato). Co-CEOs: Lee Sang-yul and Kim Hyun-ho. | IB Tomato (9 Jun 2026); TheVC |
Chunbo Advanced Materials (천보신소재) | Battery-material capacity and new-process development; IR names its site "Yeongpyeong" (영평) | — | Chunbo 2Q24 IR deck (Sep 2024) |
Chunbo Precision (천보정밀) | Group company referred to in the IR history slide | — | Chunbo 2Q23 and 2Q24 IR decks |
Associate(s) | Equity-method investment of KRW 4.35bn (Jun 2026) | — | Valueline/DataHero |
Revenue by Segment
| Segment | FY2024 | FY2025 |
|---|---|---|
Secondary battery materials (KRW Bn) | 77.2 | 67.9 |
Electronic materials (KRW Bn) | 49.0 | 51.4 |
Pharma + fine chemicals + other (KRW Bn) | 18.7 | 14.5 |
Total revenue (KRW Bn) | 144.9 | 133.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2024 | FY2025 |
|---|---|---|
Secondary battery materials (%) | 53.3 | 50.7 |
Electronic materials (%) | 33.8 | 38.4 |
Pharma + fine chemicals + other (%) | 12.9 | 10.8 |
Segment Revenue
| Segment | FY2022 basis (reported Apr 2023) | Q2 2026 |
|---|---|---|
Secondary battery materials | 68.0 | 58 |
Electronic materials | 23.8 | 29 |
Other | 4.0 | 8 |
Fine chemicals | 2.4 | 2 |
Pharmaceutical materials | 1.8 | 3 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 271.6 | 328.9 | 182.7 | 144.9 | 133.8 |
Operating income (KRW Bn) | 50.6 | 56.5 | -8.0 | -22.8 | 3.7 |
Net income incl. NCI (KRW Bn) | 48.0 | 42.8 | -45.5 | -32.3 | -60.0 |
Revenue growth YoY (%) | 74.7 | 21.1 | -44.5 | -20.7 | -7.6 |
Operating margin (%) | 18.6 | 17.2 | -4.4 | -15.7 | 2.8 |
Net margin (%) | 17.7 | 13.0 | -24.9 | -22.3 | -44.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net income attributable to owners (KRW Bn) | 37.4 | -41.8 | -27.4 | -57.8 |
Basic EPS (KRW) | 3,736 | -4,175 | -2,740 | -5,550 |
Pre-tax income (KRW Bn) | 0 | -42.4 | -27.7 | -62.8 |
EBITDA (KRW Bn) | 76.0 | 11.7 | -3.2 | 26.5 |
Business Lines
| Line (FY2025) | KRW Bn |
|---|---|
Revenue | 133.85 |
Cost of sales | 120.41 |
— of which raw materials | 55.42 |
— of which labour | 10.65 |
— of which depreciation | 21.76 |
Gross profit | 13.43 |
SG&A | 9.72 |
— of which R&D expense (in SG&A) | 1.27 |
Operating income | 3.71 |
Financial income | 15.65 |
— of which derivative gains | 12.20 |
Financial costs | 81.35 |
— of which interest expense | 22.60 |
— of which derivative losses | 58.75 |
Other non-operating, net | -1.67 |
Pre-tax loss | -62.83 |
Income tax (benefit) | -2.81 |
Net loss | -60.01 |
Net loss attributable to owners | -57.77 |
Gross Margin by Period
| Period | Gross margin | Source |
|---|---|---|
FY2025 | 10.0% (derived) | Valueline |
9M 2024 | Gross loss of KRW 14.1bn | Quartr Q3 2025 summary |
9M 2025 | 13.3% | Quartr Q3 2025 summary |
H1 2025 | 15.1% | Quartr Q2 2026 summary |
H1 2026 | –3.3% (start-up depreciation at Saemangeum) | Quartr Q2 2026 summary |
TTM to Jun 2026 | Essentially zero gross profit (KRW 0.01bn) | Valueline |
Income Statement
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 35.6 | 33.0 | 30.6 | 34.6 | 40.8 | 51.0 |
Operating income (KRW Bn) | 2.8 | 2.9 | 0.6 | -2.6 | -3.4 | -3.8 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 818.7 | 933.7 | 1,007.9 | 849.5 | 907.9 |
Current assets (KRW Bn) | 439.4 | 281.9 | 247.4 | 125.9 | 169.2 |
Cash & equivalents (KRW Bn) | 64.8 | 60.8 | 15.9 | 15.5 | 16.0 |
Short-term financial instruments (KRW Bn) | 201.2 | 111.0 | 160.5 | 34.0 | 40.6 |
Trade receivables (KRW Bn) | 57.5 | 25.6 | 24.1 | 26.4 | 40.2 |
Inventories (KRW Bn) | 86.1 | 69.3 | 32.4 | 31.2 | 54.2 |
PP&E (KRW Bn) | 341.6 | 612.3 | 705.1 | 652.2 | 650.2 |
Construction in progress (KRW Bn) | 175.1 | 448.1 | 549.3 | 173.2 | 137.5 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Intangible assets (KRW Bn) | 1.1 | 1.0 | 0.8 | 1.4 | 1.3 |
Total liabilities (KRW Bn) | 423.8 | 583.2 | 592.9 | 382.2 | 425.5 |
Current liabilities (KRW Bn) | 148.4 | 233.4 | 489.8 | 320.3 | 379.9 |
Short-term borrowings (KRW Bn) | 48.0 | 152.0 | 127.5 | 96.8 | 99.3 |
Short-term bonds incl. current CB (KRW Bn) | 13.0 | 5.6 | 174.7 | 74.6 | 91.1 |
Current portion of LT borrowings (KRW Bn) | 9.5 | 8.5 | 46.5 | 39.5 | 35.4 |
Convertible bonds non-current (KRW Bn) | 212.2 | 220.8 | 0 | 0 | 0 |
Bonds with warrants non-current (KRW Bn) | 42.4 | 44.2 | 0 | 0 | 0 |
Long-term borrowings (KRW Bn) | 19.8 | 83.3 | 101.4 | 60.4 | 43.2 |
Total debt (KRW Bn) | 344.9 | 514.4 | 450.1 | 271.3 | 269.0 |
Short-term debt (KRW Bn) | 70.5 | 166.1 | 348.7 | 210.9 | 225.8 |
Long-term debt (KRW Bn) | 274.4 | 348.3 | 101.4 | 60.4 | 43.2 |
Cash + ST financial instruments (KRW Bn) | 266.0 | 171.8 | 176.4 | 49.5 | 56.6 |
Net debt (KRW Bn) | 78.9 | 342.6 | 273.7 | 221.8 | 212.4 |
Total equity (KRW Bn) | 394.8 | 350.5 | 414.9 | 467.4 | 482.4 |
Equity attributable to owners (KRW Bn) | 343.1 | 296.6 | 365.9 | 423.5 | 452.0 |
Hybrid capital securities in equity (KRW Bn) | 0 | 0 | 100.0 | 100.0 | 100.0 |
Non-controlling interests (KRW Bn) | 51.8 | 54.0 | 49.0 | 43.8 | 30.4 |
Working capital, CA minus CL (KRW Bn) | 291.0 | 48.5 | -242.4 | -194.4 | -210.7 |
Book value per share (KRW) | 34,308 | 29,657 | 36,590 | 36,230 | 36,886 |
Shares outstanding (millions) | 10.00 | 10.00 | 10.00 | 11.69 | 12.25 |
Cash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (KRW Bn) | 8.0 |
Capex, PP&E acquisitions (KRW Bn) | 21.5 |
Free cash flow, OCF minus capex (KRW Bn) | -13.5 |
Investing cash flow (KRW Bn) | 151.0 |
Financing cash flow (KRW Bn) | -159.4 |
Dividends paid (KRW Bn) | 0 |
Share buybacks (KRW Bn) | 0 |
Interest paid (KRW Bn) | 4.9 |
D&A (KRW Bn) | 22.8 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | 11.9 | -13.1 | -8.3 | -14.6 |
ROA (%) | 5.2 | -5.2 | -3.3 | -6.5 |
Current ratio (x) | 2.96 | 1.21 | 0.51 | 0.39 |
Debt to equity (x) | 0.87 | 1.47 | 1.08 | 0.58 |
Asset turnover (x) | 0.40 | 0.21 | 0.15 | 0.14 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | Note |
|---|---|---|---|---|---|
Net debt / EBITDA | ~1.0x | ~29x | n/m (negative EBITDA) | ~8.4x | Derived |
Interest coverage (OP / interest expense) | — | negative | negative | ~0.16x | FY2025: 3.7 / 22.6 |
ROIC (NOPAT / [equity + net debt]) | — | negative | negative | ~0.4% | FY2025, assumes 20% tax on OP |
Cash conversion cycle | — | — | — | ~151 days | FY2025 DSO ~72, DIO ~95, DPO ~16 (year-end balances) |
Gross margin | — | — | — | 10.0% | — |
EBITDA margin | 23.1% | 6.4% | -2.2% | 19.8% | Derived |
Region / Indicator Details
| Region / indicator | Data point | Date / basis | Source |
|---|---|---|---|
China share of revenue | About 40% | 2022–2023 | Dealsite (22 Aug 2023); DS Investment (8 Jun 2023) |
Management target | Cut China to 20% and raise Europe and US to 60% by end-2024 | Stated Aug 2023 | Dealsite (22 Aug 2023) |
Outcome vs target | Not achieved. Europe and US electrolyte demand stayed weak; China share rose in Q4 2025. | Jan 2026 | Kiwoom (2 Jan 2026) |
China (Q4 2025 → 2026) | LiPO2F2 shipments rising, led by EVE Energy; Chinese demand and prices drove +30% QoQ LiPO2F2 volume in Q2 2026 | Q4 2025 – Q2 2026 | Kiwoom (Jan and Aug 2026) |
North America | LiFSI shipments to a North American OEM since early 2026; LiFSI revenue estimated at KRW 1.3bn (Q1 2026) and KRW 3.6bn (Q2 2026) | 2026 | Mirae Asset (Apr 2026); Kiwoom (Aug 2026) |
Korea | Electronic materials and oxalic acid sold mainly to Korean panel and chip supply chains; Korean cell makers for battery materials | Ongoing | Company descriptions |
Japan and Taiwan | Oxalic-acid exports | Ongoing | Innoforest |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 218,300 | 110,200 | 36,350 | 49,150 |
Year-end market cap (KRW Bn) | 2,183.0 | 1,102.0 | 363.5 | 572.1 |
Year-end price to book (x) | 6.4 | 3.72 | 0.99 | 1.35 |
Share Price History
| Date | Price | Source |
|---|---|---|
2 Mar 2023 | 244,000 | Yuanta |
10 Apr 2023 | 281,500 | Yuanta |
29 Nov 2023 | 108,400 | Broker report |
17 May 2024 | 76,500 | Hanwha |
13 Nov 2024 | 44,950 | iM |
29 May 2025 | 35,650 | iM |
20 Nov 2025 | 55,900 | iM |
30 Dec 2025 | 49,150 | Kiwoom |
18 May 2026 | 50,600 | Naver/AI report |
30 Jun 2026 | 40,700 | Valueline |
4 Aug 2026 | 32,950 | Valueline |
16 Oct 2026 | 34,150 | Valueline |
19 Oct 2026 | 36,550 | Valueline |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | ~KRW 448bn | 12.25m shares |
P/E (TTM) | Negative / n.m. | TTM owners' net loss about KRW 64.6bn (Valueline, Jun 2026) |
P/B | ~0.99x | BPS KRW 36,886 (Jun 2026, includes hybrid in owners' equity). Valueline shows 0.92x on its own market cap. |
EV | ~KRW 691bn | Market cap 448 + debt 269.0 – cash and short-term instruments 56.6 + NCI 30.4. About KRW 791bn if the KRW 100bn hybrid is treated as debt. |
EV / Sales (TTM) | ~4.4x (about 5.0x with hybrid as debt) | TTM revenue KRW 157.0bn |
EV / EBITDA (TTM) | ~26x (about 30x with hybrid) | TTM EBITDA about KRW 26.8bn (OP –9.2 + D&A 36.0) |
Mirae Asset framework | 15x EV/EBITDA on 2027E | HelloT (Apr 2026) |
iM framework | P/E about 23–26x on 2027E | iM (May 2025: 23.3x; Nov 2025: 26.0x) |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (KRW) | Key estimates | Source |
|---|---|---|---|---|---|
Mirae Asset Securities | 13 Apr 2026 | Buy | 79,000 (from 68,000) | 2026E OP –KRW 3.0bn; F-product 36% (2026) and 46% (2027) of revenue; 15x 2027E EV/EBITDA | HelloT |
Kiwoom Securities | Jul 2026 (2Q26 preview) | Outperform | 45,000 | 2Q26 revenue KRW 48.5bn, OP –KRW 3.0bn | StockHub |
Kiwoom Securities | 27 Aug 2026 | Not stated | Not stated | Q4 2026 turnaround expected | StockHub |
Kiwoom Securities | 2 Jan 2026 | Marketperform | 52,000 | 2026F revenue KRW 192.6bn, OP KRW 3.7bn; 2027F OP KRW 25.6bn | Kiwoom; Aju News |
iM Securities | 21 Nov 2025 | Not stated in excerpt | Not stated in excerpt | 2026E revenue KRW 214.6bn, OP KRW 11.5bn | iM |
iM Securities | 30 May 2025 | Not stated in excerpt | 40,000 | 2025E revenue KRW 166.7bn, OP KRW 13.5bn | iM |
Consensus (5 brokers) | Date not stated | — | 51,000 | — | Butler |
Consensus (latest 90 days) | Oct 2026 | — | 45,000 (1 report) | — | StockHub |
Bucket Details
| Bucket | KRW Bn |
|---|---|
Short-term borrowings | 99.3 |
Short-term bonds (incl. current CB) | 91.1 |
Current portion of LT borrowings | 35.4 |
Total due ≤12 months | 225.8 |
Long-term borrowings | 43.2 |
Analyst Conclusions
Management guidance and consensus
No formal numerical guidance was found. Management's stated direction:
-
reach a 25% operating margin on new lithium salts through process innovation;
-
scale LiFSI for North American customers;
-
recover pricing through raw-material pass-through.
Sell-side expectations range widely. Kiwoom forecasts a 2026 operating profit of KRW 3.7bn (January) and expects a Q4 2026 turnaround (August). Mirae Asset forecasts an operating loss of KRW 3.0bn for 2026 but strong EBITDA growth into 2027. iM had forecast KRW 11.5bn (November 2025). H1 2026 actual operating profit was –KRW 7.2bn, so full-year 2026 operating profit near breakeven or negative is the realistic base case. FY2027 forecasts are the main valuation anchor (Kiwoom 2027F OP KRW 25.6bn; Mirae Asset 15x EV/EBITDA on 2027E).
Bull case (grounded in data)
-
LiFSI volume step-change. LiFSI revenue nearly tripled QoQ (KRW 1.3bn → 3.6bn) between Q1 and Q2 2026. If F-products reach 36–46% of revenue as Mirae Asset projects, utilization at the KRW 650bn asset base rises and EBITDA margins should rise sharply on fixed-cost leverage.
-
Sector tailwind. Chinese peers are near full utilization (Tinci H1 2026 net profit +968%). Tight salt and electrolyte markets plus LiPF6 price increases support ASP recovery and about 20% raw-material pass-through from H2 2026.
-
Valuation on assets. At about 0.99x P/B and roughly KRW 450bn market cap against KRW 650bn of mostly new PP&E, the market pays little for replacement value. The capex cycle has largely ended (construction in progress down 68% in FY2025), so the free-cash-flow profile can improve quickly if utilization rises.
Bear case (grounded in data)
-
Earnings quality and dilution. Net losses have continued for three years (–KRW 60.0bn in FY2025). About 2.34m further shares from CB conversion (about 19%) and potential minority dilution at Chunbo BLS (up to about 26%) limit per-share upside even if operations recover.
-
Liquidity. A 0.39x current ratio, KRW 225.8bn of debt due within 12 months, and FY2025 OCF of only KRW 8.0bn mean the company depends on continuous refinancing. The August 2026 collateral-provision filing and the subsidiary CB terms (IPO deadline, EBITDA reset) add contingent pressure.
-
Structural competitive disadvantage. The 2026 upcycle is lifting Chinese scale players far faster than Chunbo (H1 revenue +109% at Tinci vs +34% at Chunbo, which is still loss-making). The non-China premium remains uncertain under current US policy, and the LiFSI ramp depends on a single OEM program.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (expected mid-November 2026). Gross margin back to positive? Progress toward the Q4 turnaround Kiwoom expects.
-
Quarterly LiFSI revenue. Can it exceed about KRW 10bn per quarter (implied by the 36% F-mix target)? Disclosure of Saemangeum utilization.
-
Korean LiPO2F2 export data (KITA) as a monthly real-time proxy.
-
LiPF6 and lithium carbonate prices, and contract pass-through outcomes.
-
Remaining conversion of the KRW 101.9bn 6th-series CB, and any new mezzanine issuance at the parent.
-
Chunbo BLS IPO preparation and compliance with CB covenants.
-
US policy: FEOC rules for components, and any duties on China-origin electrolyte salts.
-
Volume of the North American OEM's 4680 / Cybercab program.
-
FY2026 annual report (Mar 2027): debt refinancing, hybrid terms, derivative remeasurement.
-
Insider and major-shareholder filings (follow-ups to the Jul–Aug 2026 reports).
Analyst verdict
Chunbo is a high-quality chemistry business attached to a strained balance sheet, and its main investment has not yet earned a return. Its technical claims hold up: it commercialized LiFSI first, it remains a reference supplier of LiPO2F2, and its electronic-materials franchise still produces roughly KRW 50bn a year at about 20% margins. The difficulty is financial and structural, not technological. Between 2021 and 2025 the company invested roughly KRW 650bn of assets into a market that Chinese producers then oversupplied. Delays at Saemangeum meant its new capacity arrived after prices had collapsed.
The 2026 situation has improved. Quarterly revenue has risen for three straight quarters to KRW 51bn. LiFSI is shipping to a North American OEM. The capex cycle is largely complete. Chinese peers' results show the electrolyte chain is in a genuine upcycle. On about 0.99x book value, the market is not pricing in success.
However, the improvement has not yet reached reported earnings. Gross margin was negative in H1 2026, interest costs exceed operating profit, and every equity rebuild since 2024 has come through conversions that dilute minorities. With about 19% more parent dilution outstanding and contingent claims at the Chunbo BLS level, value created by the turnaround will be shared heavily with mezzanine holders.
On balance, Chunbo is a speculative, catalyst-driven turnaround, not a quality compounder. The key evidence to watch is whether quarterly LiFSI revenue reaches double-digit KRW billions and gross margin returns to 15% or more before the next refinancing window. If both happen by mid-2027, FY2027 EBITDA in the KRW 60–80bn range becomes plausible and current multiples are undemanding. If they do not, the balance sheet will force another dilutive financing at a lower price. Position sizing should reflect a wide range of outcomes. Investors should wait for the Q3 and Q4 2026 results to confirm the turnaround Kiwoom expects rather than buy ahead of it.
SOURCES CONSULTED (selection)
Chunbo IR presentations: 2Q21 (Aug 2021), 4Q21 (Feb 2022), 2Q22 (Aug 2022), 3Q22 (Nov 2022), 1Q23 (Apr 2023; BofA conference May 2023), 2Q23 (Aug 2023), 2Q24 (Sep 2024)
Earnings summaries: Quartr Chunbo summaries (Q2 2024 – Q2 2026); Quartr Enchem summaries
DART-based financial aggregators: Valueline/DataHero balance sheet, income statement and cash flow (accessed 19 Oct 2026); Butler.works (OpenDART); Bullstory (OpenDART)
Broker research: - Kiwoom Securities: 8 Jul 2024; 2 Jan 2026; 2Q26 preview; 27 Aug 2026 via StockHub
-
iM / Hi Investment & Securities: Nov 2023, Jan 2024, mid-2024, Nov 2024, 30 May 2025, 21 Nov 2025
-
Mirae Asset Securities (via HelloT, 13 Apr 2026)
-
Daishin (Mar 2022, Aug 2022, Jul 2023); Yuanta (Mar and Apr 2023); Hanwha (May 2024); DS Investment (Jun 2023)
-
Research Alum (via Asia Economy, 25 Aug 2025)
-
Naver AI company report (20 May 2026)
Press: - IB Tomato: 2 May 2023; 24 Jul 2025; 9 Jun 2026
-
Dealsite: 25 Apr 2023; 22 Aug 2023
-
Digital Daily: 30 Apr 2023; 10 Feb 2026
-
MTN: 12 Oct 2022
-
TheElec: 25 Jan 2021
-
Newsis and Jeonbuk Ilbo: 7 Jul 2021
-
Asia Economy and Energy Economy: 8 Oct 2018
-
Aju News: 2 Jan 2026
-
Edaily via Techleap: Jan 2026
Industry context: Mysteel (Tinci and Capchem H1 2026, 21 Aug 2026; EVE–Fluence, 18 Sep 2026; China battery data); Tiger Brokers (Capchem FY2025); MarketGrowthReports (LiFSI penetration; low-confidence source)
Company profiles: Komachine, Innoforest, TheVC, Craft.co, Koalagains, StockHub
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / role | Compensation |
|---|---|---|---|
Lee Sang-yul (이상율) | CEO and Representative Director; founder and controlling shareholder; also CEO of Chunbo BLS | CEO since at least listing (2019). Led the company through the LiFSI commercialization. | Not publicly disclosed in sources reviewed (Korean individual pay disclosure applies only above KRW 500m) |
Lee Dong-ho (이동호) | CFO / Executive Director (전무) | Public IR spokesman (2023) | — |
Kim Hyun-ho (김현호) | Co-CEO, Chunbo BLS | Current (TheVC listing) | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Lee Sang-yul and 11 related parties | 55.9% | Dec 2025 / Jan 2026 | Kiwoom (2 Jan 2026) |
Lee Sang-yul and related parties (earlier) | 55.4% | 2023–2024 | Hanwha (May 2024); DS (Jun 2023) |
Treasury shares | 0.56% to 0.7% | 2024–2026 | Butler; Hanwha |
Foreign ownership | 2.1% | Dec 2025 | Kiwoom (Jan 2026) |
Foreign ownership (earlier) | 9.30% (Mar 2023) → 5.1% (Nov 2024) | — | Yuanta; iM |
Unconverted 6th-series CB holders | Up to about 2.34m shares (about 19% of current shares) at KRW 43,541 | Jun 2026 | IB Tomato (9 Jun 2026) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Relevance to Chunbo |
|---|---|---|---|
Lithium salts and additives / electrolyte | Guangzhou Tinci Materials | China | Global electrolyte leader with integrated LiPF6 and LiFSI |
Lithium salts and additives / electrolyte | Shenzhen Capchem | China | Electrolyte and additives; Malaysia plant due end-2026 |
Lithium salts | Do-Fluoride (DFD) | China | LiPF6 and LiFSI |
Additives | Huasheng Lithium and other Chinese VC/FEC makers | China | Price setters in VC/FEC |
LiFSI | Nippon Shokubai | Japan | LiFSI ("IONEL") |
LiFSI | Arkema | France | LiFSI |
LiPF6 / salts | Foosung | Korea | Korean fluorine salts (named by Koalagains) |
LiPF6 | PGT | Korea | Partner since Feb 2026; adjacent rather than direct competitor |
Electrolyte (customer and competitor in additives) | Dongwha Electrolyte | Korea | Partner and customer |
Electrolyte | Enchem | Korea | Electrolyte; building LiFSI and lithium-salt capability |
Electrolyte / electronic materials | Soulbrain | Korea | Also competes in semiconductor chemicals |
Electronic chemicals | ENF Technology, Dongwoo Fine-Chem | Korea | Etchants and process chemicals |
Peer Comparison FY2025
| Company | Latest revenue | Growth | Profitability | Source |
|---|---|---|---|---|
Chunbo | FY2025 KRW 133.8bn; H1 2026 KRW 91.8bn | FY2025 –7.6%; H1 2026 +34% | FY2025 OPM 2.8%; H1 2026 OPM –7.8%; R&D (SG&A) about 0.9% | — |
Capchem | FY2025 RMB 9.639bn; H1 2026 RMB 7.463bn | FY2025 +22.84%; H1 2026 +75.66% | FY2025 gross margin 24.28%; H1 2026 net profit RMB 984m | Tiger Brokers (FY2025); Mysteel (21 Aug 2026) |
Tinci Materials | H1 2026 RMB 14.71bn | H1 2026 +109.28% | H1 2026 net profit RMB 2.861bn; FY2025 net profit guided at RMB 1.1–1.6bn | Mysteel (21 Aug 2026; 4 Jan 2026) |
Enchem | FY2025 KRW 312.8bn; H1 2026 KRW 186.4bn | FY2025 –14.5% vs KRW 365.7bn | FY2025 OP –KRW 78.4bn; going-concern uncertainty flagged | Quartr Enchem Q2 2026 summary |



